RemeGen’s telitacicept at 104 weeks: kidney function protection persists, while commercial use still depends on payment
A Chinese phase III study showed that kidney function declined more slowly over two years in the telitacicept group than in the placebo group, while improvements in proteinuria persisted. J.P. Morgan considers it competitive for high-risk IgA nephropathy patients, but treatment choices and long-term costs will affect actual use.
J.P. Morgan ·